Abstract | OBJECTIVES: The efficacy of octreotide was studied in a group of patients with biochemical evidence of insulinoma. DESIGN: A phase-II study. SETTING: A university department of internal medicine. SUBJECTS: Seven patients with biochemical evidence of insulinoma and without metastatic lesions. INTERVENTION: Daily treatment with octreotide, a somatostatin analogue, mainly within the dosage of 100-300 micrograms day-1. The treatment was continued in patients with biochemical evidence of response or until surgery was undertaken. MAIN OUTCOME: Five patients avoided hypoglycaemic symptoms and had normalization of blood glucose values for a median of 15+ months (range 0.2-54 months). Two did not improve metabolically. The treatment was well tolerated and had no deleterious effects on blood glucose regulation. CONCLUSION:
Octreotide seems to be a promising treatment for many of the patients with insulinoma who are not suitable for surgery.
|
Authors | F E von Eyben, E Grodum, H J Gjessing, C Hagen, H Nielsen |
Journal | Journal of internal medicine
(J Intern Med)
Vol. 235
Issue 3
Pg. 245-8
(Mar 1994)
ISSN: 0954-6820 [Print] England |
PMID | 8120520
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Female
- Humans
- Insulinoma
(blood, drug therapy)
- Male
- Middle Aged
- Octreotide
(therapeutic use)
- Pancreatic Neoplasms
(blood, drug therapy)
- Prospective Studies
- Time Factors
- Treatment Outcome
|